School of Pharmaceutical Sciences (FCF), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
School of Pharmaceutical Sciences (FCF), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil; Sao Leopoldo Mandic Institute, Campinas, SP, Brazil.
Biomed Pharmacother. 2024 Sep;178:117299. doi: 10.1016/j.biopha.2024.117299. Epub 2024 Aug 13.
Artemisia annua L., known for antimalarial activity, has demonstrated evidence of anti-inflammatory potential. Previously our research group reported the anti-inflammatory and antinociceptive effect of a sesquiterpene lactone-enriched fraction (Lac-FR) obtained from plant, containing artemisinin and deoxyartemisinin. Both the isolated compounds and Lac-FR evaluated on experimental animal models, in the formalin test showed that deoxyartemisinin reduced both neurogenic pain (56.55 %) and inflammatory pain (45.43 %). These findings were superior to the effect of artemisinin (reduction of 28.66 % and 33.35 %, respectively). In the tail flick test, the antinociceptive effect reported as a percentage of the maximum possible effect (%MPE), deoxyartemisinin showed a lower antinociceptive effect (41.57 %) compared to morphine (75.94 %) in 0.5 h. After 1.5 h, the MPE of deoxyartemisinin (87.99 %) exceeded the effect of morphine (47.55 %), without reversal with naloxone. The MPE of artemisinin (23.3 %) observed after 2 h was lower than deoxiartemisinin, without reversal with the opioid antagonist. Lac-FR and artemisinin demonstrated reductions in ear edema of 43.37 % and 48.19 %, respectively, higher than the effect of deoxyartemisinin (33.64 %). Artemisinin reduced tumor necrosis factor alpha (TNF-α) (76.96 %) more selectively when compared to interleukin-1beta (IL-1β) (48.23 %) and interleukin-6 (IL-6) (44.49 %). Lac-FR showed greater selectivity in IL-6 reduction (56.49 %) in relationship to TNF-α (46.71 %) and IL-1β (45.12 %), whereas deoxyartemisinin selectively reduced TNF-α (37.37 %). The results of our study indicate that the lactones isolated did not have relationship with the opioid system. Deoxyartemisinin showed a higher antinociceptive potential than artemisinin. Whereas, artemisinin showed a higher reduction of inflammation and mediators, with a better anti-inflammatory activity outcome.
黄花蒿 L.,以抗疟活性而闻名,具有抗炎潜力的证据。此前,我们的研究小组报道了从植物中获得的一种富含倍半萜内酯的馏分(Lac-FR)的抗炎和镇痛作用,其中含有青蒿素和脱氧青蒿素。在福尔马林试验中,无论是单独的化合物还是 Lac-FR 评估的实验动物模型,脱氧青蒿素都能减少神经源性疼痛(56.55%)和炎症性疼痛(45.43%)。这些发现优于青蒿素的效果(分别减少 28.66%和 33.35%)。在尾巴闪烁试验中,作为最大可能效应的百分比(%MPE)报告的镇痛作用,脱氧青蒿素在 0.5 小时时显示出比吗啡(75.94%)更低的镇痛作用(41.57%)。在 1.5 小时后,脱氧青蒿素的 MPE(87.99%)超过了吗啡(47.55%)的效果,而纳洛酮不能逆转。2 小时后观察到的青蒿素(23.3%)的 MPE 低于脱氧青蒿素,且没有阿片类拮抗剂逆转。Lac-FR 和青蒿素分别显示出 43.37%和 48.19%的耳部水肿减少,高于脱氧青蒿素的作用(33.64%)。与白细胞介素-1β(IL-1β)(48.23%)和白细胞介素-6(IL-6)(44.49%)相比,青蒿素对肿瘤坏死因子-α(TNF-α)(76.96%)的选择性降低更为明显。Lac-FR 在降低白细胞介素-6(56.49%)方面的选择性更高,与 TNF-α(46.71%)和 IL-1β(45.12%)相比,而脱氧青蒿素则选择性地降低 TNF-α(37.37%)。我们的研究结果表明,分离出的内酯与阿片样物质系统无关。脱氧青蒿素的镇痛潜力高于青蒿素。然而,青蒿素表现出更高的炎症和介质减少,具有更好的抗炎活性结果。